We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
- Authors
Tauber, E; Kollaritsch, H; von Sonnenburg, F; Lademann, M; Jilma, B; Firbas, C; Jelinek, T; Beckett, C; Knobloch, J; McBride, W J H; Schuller, E; Kaltenböck, A; Sun, W; Lyons, A
- Abstract
Japanese encephalitis (JE) is the most important mosquito-borne viral encephalitis and has a high case fatality rate. It is caused by Japanese encephalitis virus. Improved vaccines are urgently needed for residents in countries of endemicity, travelers, and the military. The aim of the present trial was to evaluate the safety and tolerability of IC51, Intercell's Vero cell-derived, purified, inactivated JE vaccine.
- Publication
The Journal of infectious diseases, 2008, Vol 198, Issue 4, p493
- ISSN
0022-1899
- Publication type
Journal Article
- DOI
10.1086/590116